CAR-T Cell Safety Assessment: A Non-Clinical Safety Evaluation Study of Nanoparticle-Delivered CAR-T Cells
Chimeric antigen receptor (CAR) T cell therapy is a promising cancer treatment approach. However, traditional CAR-T engineering relies on viral vectors, which pose several challenges, including permanent CAR expression, high production costs, and safety concerns such as cytokine release syndrome and neurotoxicity. mRNA-lipid nanoparticle (mRNA-LNP) delivery is a cost-effective alternative, enabling temporary CAR expression and reduced toxicity.
In this study, we assessed mRNA-LNP-delivered CAR-T cells in a myeloma mouse model, investigating:
CAR-T cell efficacy
Biodistribution
Cytokine analysis
Immunophenotyping
Ophthalmological, clinical, and histological pathology
